高级检索
当前位置: 首页 > 详情页

Recent advances in the role of high-salt diet in anti- and pro-cancer progression

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Univ Sci & Technol, Sch Med, Kunming, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Yunnan Digest Endoscopy Clin Med Ctr, Dept Gastroenterol, Kunming, Yunnan, Peoples R China [3]First Peoples Hosp Yunnan Prov, Yunnan Prov Clin Res Ctr Senile Dis, Kunming, Yunnan, Peoples R China [4]Med Prod Adm Yunnan Prov, Yunnan Inst Food & Drug Supervis & Control, Kunming, Yunnan, Peoples R China [5]Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Peoples R China [6]Guangzhou Med Univ, Guangdong Hongkong Macao Joint Lab Resp Infect Dis, Guangzhou, Guangdong, Peoples R China [7]First Peoples Hosp Yunnan Prov, Yunnan Prov Key Lab Clin Virol, Kunming, Yunnan, Peoples R China [8]First Peoples Hosp Yunnan Prov, Yunnan Prov Key Lab Birth Defects & Genet Dis, Kunming, Yunnan, Peoples R China
出处:
ISSN:

关键词: high-salt diet (HSD) immunotherapy tumor microenvironment (TME) gut microbiota sodium transporter channels

摘要:
Dietary behaviors significantly influence tumor progression, with increasing focus on high-salt diets (HSD) in recent years. Traditionally, HSD has been regarded as a major risk factor for multiple health issues, including hypertension, cardiovascular disease, kidney disease, cancer, and osteoporosis. However, recent studies have uncovered a novel aspect of HSD, suggesting that HSD may inhibit tumor growth in specific pathological conditions by modulating the activity of immune cells that infiltrate tumors and enhancing the effectiveness of PD-1 immunotherapy. This review focused on the duel molecular mechanisms of HSD in cancer development, which are based on the tumor microenvironment, the gut microbiota, and the involvement of sodium transporter channels. The objective of this review is to explore whether HSD could be a potential future oncological therapeutic strategy under specific situation.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Kunming Univ Sci & Technol, Sch Med, Kunming, Yunnan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Kunming Univ Sci & Technol, Sch Med, Kunming, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Yunnan Digest Endoscopy Clin Med Ctr, Dept Gastroenterol, Kunming, Yunnan, Peoples R China [3]First Peoples Hosp Yunnan Prov, Yunnan Prov Clin Res Ctr Senile Dis, Kunming, Yunnan, Peoples R China [7]First Peoples Hosp Yunnan Prov, Yunnan Prov Key Lab Clin Virol, Kunming, Yunnan, Peoples R China [8]First Peoples Hosp Yunnan Prov, Yunnan Prov Key Lab Birth Defects & Genet Dis, Kunming, Yunnan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:86881 今日访问量:0 总访问量:706 更新日期:2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号